463 related articles for article (PubMed ID: 10946294)
1. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
3. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma.
Shibagaki N; Udey MC
Eur J Immunol; 2003 Apr; 33(4):850-60. PubMed ID: 12672050
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.
Eggert AA; Schreurs MW; Boerman OC; Oyen WJ; de Boer AJ; Punt CJ; Figdor CG; Adema GJ
Cancer Res; 1999 Jul; 59(14):3340-5. PubMed ID: 10416590
[TBL] [Abstract][Full Text] [Related]
6. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
Ji Q; Gondek D; Hurwitz AA
J Immunol; 2005 Aug; 175(3):1456-63. PubMed ID: 16034082
[TBL] [Abstract][Full Text] [Related]
7. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination.
Matsuyoshi H; Senju S; Hirata S; Yoshitake Y; Uemura Y; Nishimura Y
J Immunol; 2004 Jan; 172(2):776-86. PubMed ID: 14707047
[TBL] [Abstract][Full Text] [Related]
8. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
9. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy.
van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG
Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein.
Zhang M; Ishii K; Hisaeda H; Murata S; Chiba T; Tanaka K; Li Y; Obata C; Furue M; Himeno K
Immunology; 2004 Aug; 112(4):567-74. PubMed ID: 15270727
[TBL] [Abstract][Full Text] [Related]
11. Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction.
Miconnet I; Coste I; Beermann F; Haeuw JF; Cerottini JC; Bonnefoy JY; Romero P; Renno T
J Immunol; 2001 Apr; 166(7):4612-9. PubMed ID: 11254719
[TBL] [Abstract][Full Text] [Related]
12. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines.
Nair SK; Boczkowski D; Snyder D; Gilboa E
Eur J Immunol; 1997 Mar; 27(3):589-97. PubMed ID: 9079797
[TBL] [Abstract][Full Text] [Related]
13. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
Tan XH; Liu C; Wan YH
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
[TBL] [Abstract][Full Text] [Related]
14. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.
DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H
J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036
[TBL] [Abstract][Full Text] [Related]
15. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
Gold JS; Ferrone CR; Guevara-Patiño JA; Hawkins WG; Dyall R; Engelhorn ME; Wolchok JD; Lewis JJ; Houghton AN
J Immunol; 2003 May; 170(10):5188-94. PubMed ID: 12734366
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
[TBL] [Abstract][Full Text] [Related]
17. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
Prins RM; Odesa SK; Liau LM
Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.
Mendiratta SK; Thai G; Eslahi NK; Thull NM; Matar M; Bronte V; Pericle F
Cancer Res; 2001 Feb; 61(3):859-63. PubMed ID: 11221870
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen.
Bridle BW; Li J; Jiang S; Chang R; Lichty BD; Bramson JL; Wan Y
J Immunol; 2010 Apr; 184(8):4269-75. PubMed ID: 20237288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
